TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Pharmacokinetics of Oral CellCept (Mycophenolate Mofetil) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participant must be between 3 months and 12 years of age~* Participant is a recipient of a first liver allograft from cadaveric or living donors~* Participant is a single-organ recipient (liver only)~* Female participants of childbearing potential must have a negative serum or urine pregnancy test with a sensitivity of at least 50 milli International Units per milliliter (mIU/mL) within one week prior to PK sampling~* Female participants of childbearing potential must use two reliable forms of contraception simultaneously unless abstinence is the chosen method~* Effective contraception must be used before beginning of PK sampling~* Participants must be able to receive oral medication~* Participants must be at least 6 months post-transplant and had started on MMF in the early post-transplant period (within 2 weeks of transplant)~* Participants must be receiving stable doses of MMF per center practice for at least 7 days prior to PK sampling~* In addition, participants must be receiving stable doses of cyclosporine and corticosteroids, according to center practice~* Participants' parent/guardian are capable of understanding the purposes and risks of the study and must sign an informed consent for the study~Exclusion Criteria:~* Pregnant or nursing adolescents~* Participants who had undergone dialysis within two weeks before PK sampling~* Participants with active systemic infections~* Participants with absolute neutrophil counts (ANC) of less than 1300 per microliter (µL), or platelets counts less than 50 000/µL or hemoglobin at a concentration below a set lower limit (according to center practice, but not less than 8 grams per deciliter) at the time of study entry~* Participants with active peptic ulcer disease~* Participants with severe diarrhea (more than 5 watery stools per day) or other gastrointestinal disorders which might interfere with their ability to absorb oral medication~* History of positive human immunodeficiency virus (HIV) test

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Mycophenolate Mofetil+Corticosteroids+Cyclosporine (Type: EXPERIMENTAL): Part 1: Participants will receive mycophenolate mofetil. Part 2: Participants will receive mycophenolate mofetil along with cyclosporine and corticosteroids.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Nebulized Heparin Versus Placebo for Inhalation Trauma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Age \> 18 years~* Need for invasive mechanical ventilation~* Confirmed inhalation trauma (bronchoscopically)~Exclusion Criteria:~* \> 36 hours after trauma~* Receiving invasive ventilation \> 24 hours~* Expected duration of mechanical ventilation \< 24 hours~* Chronic obstructive pulmonary disease GOLD stage III and IV~* Any history of pulmonary hemorrhage in the past 3 months~* Any history of significant bleeding disorder~* Known allergy to heparin, including heparin-induced thrombocytopenia~* Pregnancy or breast feeding~* Unlikely to survive for \> 72 hours~* Total body surface area (TBSA) \> 60%~* Witnessed or proven aspiration (i.e., confirmed by bronchoscopy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- unfractionated heparin (Type: EXPERIMENTAL): 25.000 IU/5 ml, will be nebulized 4 hourly (i.e. 6 times daily)
- placebo (Type: PLACEBO_COMPARATOR): Sterile sodium chloride (NaCl 0.9%, Pfizer), in 5 ml, will be nebulized every 4 hours (i.e. 6 times daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Intraspinal Nerve Root Stimulation With Dorsal Column Stimulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Have chronic low back pain following spine surgery (Failed Back Surgery Syndrome.~* Be an appropriate candidate for Spinal Cord Stimulation (SCS) and for the surgical procedures required for SCS.~* Have experienced significant though short-lived pain relief with local anesthetic injection.~* Be 18 years of age or older.~* Be willing and able to comply with all study related procedures and visits.~* Be capable of reading and understanding patient information materials and giving written informed consent.~Exclusion Criteria:~* Have any significant medical condition that is likely to interfere with study procedures.~* Have any evidence of neurologic instability.~* Have any other chronic pain condition.~* Have a condition currently requiring or likely to require the use of MRI or diathermy.~* Have an active implantable device.~* Are pregnant or planning to become pregnant in the next year.~* Are a current substance abuser (including alcohol and illicit drugs).~* Have a significant psychiatric disorder.~* Have participated in any drug or device trial in the last 4 weeks or plan to participate in any other trial during the duration of this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: SLEEP ON Your SIDE (SOS) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is adult~2. Either: Treatment naïve, or PAP non-complier (defined as current AAP user with \<3 hours per night in the last 3 months per compliance download), and willing to use the APAP device per protocol~3. Diagnosis of POSA meeting all the following criteria per control PSG within 6 months of screening: AHI of \>15 during PSG with symptoms of sleepiness per Investigator discretion, or AHI of \>15 during respiratory polygraphy with comorbidities (e.g. atrial fibrillation, resistant hypertension, etc.)~4. Supine AHI at least twice the lateral AHI~5. Lateral AHI \<10~6. Supine time \>30% and \<70%~7. Understands the study protocol and is willing and able to comply with study requirements and sign informed consent. APAP non-compliant subjects must be willing to use their APAP device per protocol.~Exclusion Criteria:~1. Prior or current therapy or treatment for OSA (for Treatment naïve group); Greater than an average of 3 hours per night of APAP use (in the APAP non-complier group)~2. A female of child-bearing potential that is pregnant or intends to become pregnant~3. Any unstable or severe medical condition of any organ system that at the discretion of the site Principal Investigator (PI) might affect the patient's participation in the study or generalization of treatment results~4. Taking medication that at the discretion of the site Principal Investigator (PI) might affect the patient's participation in the study or generalization of treatment results~5. Oxygen use~6. The presence of any other sleep disorder (central sleep apnea (CSA \>5), periodic limb movement disorder (PLMAI \>15), clinical diagnosis of insomnia or narcolepsy)~7. Excessive alcohol consumption (\>21 drinks/week)~8. The use of any illegal drug(s), per subject report~9. Night or rotating shift work~10. Severe claustrophobia~11. Shoulder, neck, or back complaints that restrict sleeping position~12. Subject requires use of more than 2 pillows under the head while sleeping or sleeps in a bed/chair with raised upper body position

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NightBalance Sleep Position Therapy (Type: EXPERIMENTAL): NightBalance Sleep Position Trainer (SPT) avoids POSA patients from sleeping on their back by delivering a vibrational stimulus, via a small device which is worn in a chest strap during sleep, each time the patient rolls to their back. This prompts the patient to roll over onto their side.
- Positive Airway Pressure (APAP) (Type: EXPERIMENTAL): Automatic Positive Airway Pressure (APAP) is a pump that provides a positive flow of air to keep the airway open.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Oxygen Therapy Delivery Systems in Hypoxemic Acute Respiratory Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient hospitalized in the intensive care unit of Nantes University Hospital~* Signed informed consent~* Patient with not hypercapnic acute hypoxemic respiratory failure~* Immunocompetent and immunodeficient patient~Exclusion Criteria:~* Age \< 18 years~* Pregnancy~* Contra-indication to non invasive ventilation~* Allergy to xylocaine~* Coagulation troubles~* Tracheotomized patient~* Urgent indication to intubation~* Hypercapnic acute respiratory failure~* Acute pulmonary edema~* Face or nose malformation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VNI/Optiflow, Immunodeficient patients (Type: EXPERIMENTAL): VNI = non invasive ventilation
- Optiflow/VNI, Immunodeficient patients (Type: EXPERIMENTAL): VNI = non invasive ventilation
- Ospal/Optiflow, Immunocompetent patients (Type: EXPERIMENTAL): None
- Optiflow/Ospal, Immunocompetent patients (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of NTX-001 in the Treatment and Prevention of Facial Paralysis Requiring Surgical Repair.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The subject has clinical evidence of facial paralysis requiring facial nerve repair from conditions or interventions that have or may result in paralysis.~Exclusion Criteria:~Subjects whose nerve repair will occur greater than 48 hours after nerve transection.~Subjects requiring repair of the intracranial portion of the facial nerve. Subjects requiring repair involving an allograft or conduit except for procedures that require grafting of the other nerve branches when repairing the main facial nerve.~Subjects with Bell's palsy that have signs of spontaneous recovery by 12 months.~Subjects who, in the judgment of the investigator, are not likely to demonstrate meaningful recovery within 6 weeks due to significant facial muscle atrophy.~Subjects on chronic corticosteroid therapy within 14 days of repair.~The subject has documented history or clinical signs of:~Clinically significant neuropathy from any cause i.e., medications, chemotherapy, diabetes; Clinically significant systemic neuromuscular disease; Clinically significant local or systemic neurological deficit from other than the condition under study such as stroke; Or other treatments are known to affect the growth and/or physiology of the neural and vascular system with the exception of radiation therapy; The subject has a known allergy to polyethylene glycol (PEG) or human-grade silicone.~The subject is not able to strictly adhere to the rules of the current clinical protocol, e.g., significant mental health issues, homelessness, incarceration, intellectually or developmentally challenged without proper legal representation.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- NTX-001 (Type: EXPERIMENTAL): Solution #1, Solution #2 Active, Solution #3
- Standard of Care (Type: NO_INTERVENTION): Standard neurorrhaphy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with CD30 positive Hodgkin Lymphoma (HL) or anaplastic large cell lymphoma (ALCL) that have undergone allogeneic or haploidentical SCT in the past 60 days (matched related or matched unrelated donors only).~2. Age 18 to 65 years.~3. Performance status: Zubrod 0-1 or Karnofsky 80-100.~4. Serum creatinine \< 1.5 mg/dL or creatinine clearance greater than or equal to 40 cc/min as defined by MDRD method from National Kidney Disease Education Program (NKDEP).~5. Serum direct bilirubin \< 1.5 mg/dL (unless Gilbert's syndrome).~6. SGPT \< 200 IU/L unless related to patient's malignancy.~7. Evidence of neutrophil and platelet engraftment, defined as platelet count equal or greater than 50,000 mm3 independent of platelet transfusion and ANC equal or greater to 1000 without growth factor support for at least 5 days.~8. Patients with previous exposure to brentuximab pre-transplant are eligible for the study.~Exclusion Criteria:~1. Pregnancy or breast-feeding (women of childbearing potential, any female who has experienced menarche and who has not undergone surgical sterilization or is post-menopausal with a positive serum pregnancy test.~2. Presence of steroid-refractory acute graft-versus-host disease (GVHD).~3. Patients that underwent allogeneic transplantation as a treatment of graft failure.~4. Dual refractory CMV reactivation to foscarnet and ganciclovir or evidence of CMV disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Brentuximab Vedotin (Type: EXPERIMENTAL): Brentuximab by vein over 30 minutes every 3 weeks for a total of 6 cycles starting between days 30 and 60 post allogeneic stem cell transplant (SCT).~Brentuximab dose based on actual body weight starting with an initial dose of 1.2 mg/kg for the first 2 cycles and dose increased to 1.8 mg/kg after the second cycle for all subsequent cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Development and Evaluation of a New Diagnostic Test in Female Urinary Stress Incontinence

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient must have given his/her informed and signed consent~* The patient must be insured or beneficiary of a health insurance plan~* The patient is available for 60 weeks of follow-up~* Candidate for stress urinary incontinence surgery by TVT or TOT procedures~* Positive cough or valsalve maneuver test~Exclusion Criteria:~* The patient is participating in another study (except the PISQ-R study)~* The patient is in an exclusion period determined by a previous study~* The patient is under judicial protection, under tutorship or curatorship~* The patient refuses to sign the consent~* It is impossible to correctly inform the patient~* The patient is pregnant, parturient, or breastfeeding~* The patient has a contra-indication for stress urinary incontinence surgery via TVT or TOT procedures.~* The patient has an untreated vaginal or urniary infection~* The patient has a history of allergy to polyurethane and / or Watershed XCX11122

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients (Type: EXPERIMENTAL): Women with stress urinary incontinence schelduled for TVT or TOT procedures. See inclusion/exclusion criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Computerized Cognitive Training in Young Adults With Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-29.~2. Current diagnosis of MDD/persistent depressive disorder or HDRS greater than or equal to 12. 3. Daily access to smartphone or tablet with internet connection for the study duration.~4. Willing and able to complete MRI, mood, and neuropsychological testing. 5. IQ \> 85.~Exclusion Criteria:~1. Lacks English-speaking ability as determined by self-report and clinical evaluation.~2. Evidence of schizophrenia, schizoaffective disorder, psychosis, bipolar I and II disorder.~3. Active suicidal ideation, intent, or plan, or past attempt within 1 year.~4. Severe depression (HDRS \> 30).~5. Neurological disorder (epilepsy, multiple sclerosis, traumatic brain injury, clinical stroke).~6. Use of medications known to have negative impact on cognition (benzodiazepines and lorazepam equivalents \> 1mg daily, narcotics, anticholinergics).~7. History of alcohol or drug abuse or dependence within past year.~8. Acute, severe, unstable medical illness. For cancer, acutely ill patients (including those with metastases) are excluded, but past history of successfully treated cancer does not result in exclusion.~9. Regular online brain training or regular player of non-fluency verbal games, defined as doing these procedures at a frequency of twice weekly or greater during the year prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 29 Years
- Healthy Volunteers: t

Study Arms:
- EF/PS CCT (Type: EXPERIMENTAL): This group will complete EF/PS (executive functioning/processing speed) computerized cognitive training (CCT) which includes games specifically focused on executive function \& processing speed.
- Verbal CCT (Type: ACTIVE_COMPARATOR): This group will complete verbal-focused computerized cognitive training.
- Waitlist Control (Type: PLACEBO_COMPARATOR): This group will not receive cognitive training during study participation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between High-density Electroencephalography and Conventional Electroencephalography for Comatose Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* post anoxic coma~* over 18 years old~* agreement from families~* alive 4 days after the beginning of coma~Exclusion Criteria:~* traumatic coma~* non-traumatic but not anoxic coma~* patients with severe comorbidity previous to coma~* refusal of families to participate to the study~* contraindication to a high-density electroencephalography exam

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- electroencephalography recording (Type: EXPERIMENTAL): Cerebral measurements from high-density and conventional electroencephalography are recorded simultaneously

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues